Abstract
Nuclear Hormone Receptors (NR) represent one of the most promising protein families in terms of therapeutic applications. These transcription factors are naturally switched on and off by small molecule hormones presenting physico-chemical properties very similar to therapeutic chemical entities. NRs represent therefore intrinsically a very good family of protein targets for the prevention and treatment of diverse diseases, including cancer. Several known anti-cancer drugs, such as tamoxifen or flutamide, are targeting NRs, and many more are expected to reach market. The detailed knowledge of the structural mechanism underlying activation and inhibition of NRs by small molecule modulators begets important therapeutic opportunities. The crystal structure of at least nine NR ligand binding domains (LBDs) revealed at the atomic level how natural or synthetic agonists and antagonists can promote recruitment of co-activator and co-repressor proteins. Interestingly, it was recently shown that nucleotide polymorphisms located in NR LBDs could alter or even reverse the response of the receptors to small molecule ligands. Mapping these polymorphisms on the structure of the LBD can reveal why agonists or antagonists become inactive against the mutated receptor, allow atomic models for resistance to cancer therapy, and open the door to the rational design of improved anti-cancer drugs, customized for each patient.
Keywords: pharmacogenomics, nuclear receptor, nuclear hormone receptors, anti-cancer drugs, androgen receptor, prostate cancer pharmacotherapy, acute promyelocytic leukemia, anti-proliferative and pro-differentiative effects
Current Cancer Drug Targets
Title: Pharmacogenomics Opportunities in Nuclear Receptor Targeted Cancer Therapy
Volume: 2 Issue: 3
Author(s): M. Schapira
Affiliation:
Keywords: pharmacogenomics, nuclear receptor, nuclear hormone receptors, anti-cancer drugs, androgen receptor, prostate cancer pharmacotherapy, acute promyelocytic leukemia, anti-proliferative and pro-differentiative effects
Abstract: Nuclear Hormone Receptors (NR) represent one of the most promising protein families in terms of therapeutic applications. These transcription factors are naturally switched on and off by small molecule hormones presenting physico-chemical properties very similar to therapeutic chemical entities. NRs represent therefore intrinsically a very good family of protein targets for the prevention and treatment of diverse diseases, including cancer. Several known anti-cancer drugs, such as tamoxifen or flutamide, are targeting NRs, and many more are expected to reach market. The detailed knowledge of the structural mechanism underlying activation and inhibition of NRs by small molecule modulators begets important therapeutic opportunities. The crystal structure of at least nine NR ligand binding domains (LBDs) revealed at the atomic level how natural or synthetic agonists and antagonists can promote recruitment of co-activator and co-repressor proteins. Interestingly, it was recently shown that nucleotide polymorphisms located in NR LBDs could alter or even reverse the response of the receptors to small molecule ligands. Mapping these polymorphisms on the structure of the LBD can reveal why agonists or antagonists become inactive against the mutated receptor, allow atomic models for resistance to cancer therapy, and open the door to the rational design of improved anti-cancer drugs, customized for each patient.
Export Options
About this article
Cite this article as:
Schapira M., Pharmacogenomics Opportunities in Nuclear Receptor Targeted Cancer Therapy, Current Cancer Drug Targets 2002; 2 (3) . https://dx.doi.org/10.2174/1568009023333845
DOI https://dx.doi.org/10.2174/1568009023333845 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Circulating Levels of Angiogenic Cytokines in Waldenstrom’s Macroglobulinemia: Clinical Correlations
Current Angiogenesis (Discontinued) Evolution and Structure of API5 and Its Roles in Anti-Apoptosis
Protein & Peptide Letters Radiation Dosimetry Aspects of <sup>177</sup>Lu
Current Radiopharmaceuticals The Metastatic Process: Methodological Advances and Pharmacological Challenges
Current Medicinal Chemistry Immune Response Manipulation: Recombinant Immunoreceptors Endow T-Cells with Predefined Specificity
Current Pharmaceutical Design Human Reduced Folate Carrier Gene and Transcript Variants: Functional, Physiologic, and Pharmacologic Consequences
Current Pharmacogenomics Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
Current Medicinal Chemistry Epigenetic Interventions Increase the Radiation Sensitivity of Cancer Cells
Current Pharmaceutical Design Peptides for In Vivo Target-Specific Cancer Imaging
Mini-Reviews in Medicinal Chemistry Epigenetic Effects of Environmental Chemicals on Reproductive Biology
Current Drug Targets Effects of the Natural Isoflavonoid Genistein on Growth, Signaling Pathways and Gene Expression of Matrix Macromolecules by Breast Cancer Cells
Mini-Reviews in Medicinal Chemistry Synthesis and In Vitro Biochemical Evaluation of a Series of Cycloalkyl Esters of 4-Sulfamoylated Benzoic Acid as Inhibitors of Estrone Sulfatase (ES)
Letters in Drug Design & Discovery Unified Multi-target Approach for the Rational in silico Design of Anti-bladder Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design The Role of Major Histocompatibility Complex Polymorphisms in the Incidence and Outcome of Non-Hodgkin Lymphoma
Current Immunology Reviews (Discontinued) A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Pharmacogenetics of Oxazaphosphorines and its Clinical Implications
Current Pharmacogenomics Dietary Small Molecules and Large-Scale Gene Expression Studies: An Experimental Approach for Understanding their Beneficial Effects on the Development of Malignant and Non-Malignant Proliferative Diseases
Current Medicinal Chemistry